Benjamin Hoar
Patent Agent
Dr. Benjamin (Ben) Hoar is a patent agent in the Century City office of Wilson Sonsini Goodrich & Rosati, where he focuses patent work related to software, artificial intelligence, clean energy technology, and applications of artificial intelligence in the biotech and medical device domains.
Ben obtained his Ph.D. in chemistry from UCLA in 2023 for research into applications of machine learning in electrochemistry. His work spanned the electrochemical device and process optimization, computer vision, natural language processing, education, and clean tech fields.
Prior to UCLA, Ben gained experience in biosensing at the University of Miami. He has published in each of these fields while also having studied photocatalysis UT Austin.
Experience
Dr. Benjamin (Ben) Hoar is a patent agent in the Century City office of Wilson Sonsini Goodrich & Rosati, where he focuses patent work related to software, artificial intelligence, clean energy technology, and applications of artificial intelligence in the biotech and medical device domains.
Ben obtained his Ph.D. in chemistry from UCLA in 2023 for research into applications of machine learning in electrochemistry. His work spanned the electrochemical device and process optimization, computer vision, natural language processing, education, and clean tech fields.
Prior to UCLA, Ben gained experience in biosensing at the University of Miami. He has published in each of these fields while also having studied photocatalysis UT Austin.
Education
- Ph.D., Chemistry, University of California, Los Angeles, 2023
- M.S., Chemistry, University of California, Los Angeles, 2020
- B.S., Chemistry, University of Miami, 2018
Admissions
- U.S. Patent and Trademark Office
Credentials
Education
- Ph.D., Chemistry, University of California, Los Angeles, 2023
- M.S., Chemistry, University of California, Los Angeles, 2020
- B.S., Chemistry, University of Miami, 2018
Admissions
- U.S. Patent and Trademark Office
Select Publications
- Co-author with R. Ramachandran, M. Levis-Fitzgerald, E.M. Sparck, K. Wu, and C. Liu, “Enhancing the Value of Large-Enrollment Course Evaluation Data Using Sentiment Analysis,” Journal of the Chemical Education, 2023
- Co-author with W. Zhang, S. Xu, R. Deeba, C. Costentin, Q. Gu, and C. Liu, “Electrochemical Mechanistic Analysis from Cyclic Voltammograms Based on Deep Learning,” ACS Measurement Science, Au, 2022
- Co-author with Y. Chen, J. Wang, and C. Liu, “Machine Learning-Based Inverse Design for Electrochemically Controlled Microscopic Gradients of O2 and H2O2,” PNAS, 2022
- Co-author with S. Lu, and C. Liu, “Machine-Learning-Enabled Exploration of Morphology Influence on Wire-Array Electrodes for Electrochemical Nitrogen Fixation,” The Journal of Physical Chemistry Letters, 2020
- Co-author with S.K. Karma, M. Micic, S. Li, S. Paudyal, E.M. Zahran, and R.M. Leblanc, “Conjugation of Carbon Dots with β-Galactosidase Enzyme: Surface Chemistry and Use in Biosensing,” Molecules, 2019
Insights
Select Publications
- Co-author with R. Ramachandran, M. Levis-Fitzgerald, E.M. Sparck, K. Wu, and C. Liu, “Enhancing the Value of Large-Enrollment Course Evaluation Data Using Sentiment Analysis,” Journal of the Chemical Education, 2023
- Co-author with W. Zhang, S. Xu, R. Deeba, C. Costentin, Q. Gu, and C. Liu, “Electrochemical Mechanistic Analysis from Cyclic Voltammograms Based on Deep Learning,” ACS Measurement Science, Au, 2022
- Co-author with Y. Chen, J. Wang, and C. Liu, “Machine Learning-Based Inverse Design for Electrochemically Controlled Microscopic Gradients of O2 and H2O2,” PNAS, 2022
- Co-author with S. Lu, and C. Liu, “Machine-Learning-Enabled Exploration of Morphology Influence on Wire-Array Electrodes for Electrochemical Nitrogen Fixation,” The Journal of Physical Chemistry Letters, 2020
- Co-author with S.K. Karma, M. Micic, S. Li, S. Paudyal, E.M. Zahran, and R.M. Leblanc, “Conjugation of Carbon Dots with β-Galactosidase Enzyme: Surface Chemistry and Use in Biosensing,” Molecules, 2019
Diagnostics and Medical Devices
- Bioinformatic
- Biosensors
- Medical imaging
- Wearable analyte sensors
Chemistry and Material Science
- Catalysis
- Chemistry
- Materials chemistry
- Nanochemistry
- Photovoltaic materials
Engineering and Technology
- AI
- Computer science
- Machine learning
- Materials science
Technical Fluency
Diagnostics and Medical Devices
- Bioinformatic
- Biosensors
- Medical imaging
- Wearable analyte sensors
Chemistry and Material Science
- Catalysis
- Chemistry
- Materials chemistry
- Nanochemistry
- Photovoltaic materials
Engineering and Technology
- AI
- Computer science
- Machine learning
- Materials science
Recent Insights
Client Highlights
Wilson Sonsini Advises Cytovale on IP Matters Related to $100 Million Series D Financing
On October 10, 2024, Cytovale, a commercial-stage medical diagnostics company focused on advancing early detection technologies to diagnose fast-moving and immune-mediated diseases, announced that it has raised $100 million in Series D funding. The round was led by Sands Capital, with participation from new investor Canada Pension Plan Investment Board (CPP Investments), as well as existing investors Norwest Venture Partners, Global Health Investment Corporation, and Breakout Ventures. Wilson Sonsini Goodrich & Rosati advises Cytovale on intellectual property strategy generally and advised the company on IP matters related to the Series D financing. .
Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.
The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.
For more information, please see Cytovale’s news release.
Cytovale’s IntelliSep test is the first and only U.S. Food and Drug Administration (FDA)-cleared cellular host diagnostic indicated for use in hospital emergency departments, where over 80 percent of sepsis cases present. The test, which takes only approximately eight minutes, provides clinicians with a first-ever look into the biology that causes sepsis, enabling care teams to quickly and confidently identify the proper diagnosis and deliver appropriate, patient-centered care. Cytovale will use the proceeds from the financing to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments and health systems nationwide.
The Wilson Sonsini team that advised Cytovale on IP matters related to the financing includes Matt Bresnahan, Maysam Pessian, Nicholas Tiee, and Ben Hoar.
For more information, please see Cytovale’s news release.
Learn More
Recent Events
Affiliated Programs
Startup Launchpad: Empowering Growth Through Technology & Innovation #EarlyStageLA
Wilson Sonsini is the proud presenting sponsor of #EarlyStageLA. Join us for an exciting and dynamic evening at the Startup Launchpad, where innovation meets opportunity and investment. This event is tailored for growing startups seeking to raise capital, scale their businesses, and connect with potential investors. Attendees will gain invaluable insights from industry leaders in technology, finance, legal, and HR, as well as opportunities to pitch their companies to investors and forge strategic partnerships.
Learn More
Affiliated Programs
#EarlyStageLA Launch Party: Presented by Pyrium by StartupStarter x Wilson Sonsini
Wilson Sonsini is the proud presenting sponsor of Early Stage Los Angeles. Join us for the #EarlyStageLA Launch Party, a landmark event designed to kickstart a transformative initiative for early-stage startups in the Los Angeles metropolitan area. This event marks the beginning of the city-wide effort to activate brand partnerships, venture capital funds, accelerators, universities, and promising startups, driving significant investment into the region's entrepreneurial ecosystem.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.